Pfizer stock under pressure near yearly lows despite launch of new obesity study programs

Traders Union
All News
Companies
Pfizer drops 1.02% today at $23.80

Highlights

Pfizer is trading below key moving averages, reflecting sustained bearish momentum across all time frames.
Technical indicators show deeply oversold conditions and seller dominance, with trend strength weak and no reversal signals.
Next week's forecast range is $23.50–$24.50, with limited upside potential unless resistance above $24.50 is broken.

Bearish signals persist as price trades below key moving averages

Pfizer is trading at $23.80, which is below its MA-20 ($25.66), MA-50 ($26.09), and MA-200 ($25.88), indicating persistent bearish pressure across short-, medium-, and long-term trends. The Ichimoku Kijun on D1 stands at $25.24, positioning it as immediate resistance above the current price; near-term support is around MA-5 ($25.02), while key support comes from MA-20 ($25.66). Immediate resistance is the Kijun ($25.24), with key resistance at MA-50 ($26.09).

Oversold momentum intensifies as stock tests weekly support zone

Momentum signals on D1 remain decisively negative, with the MACD showing a sell signal and ADX indicating a weak trend. Both RSI and Stoch RSI on D1 are oversold, while CCI is also in oversold territory, collectively suggesting the stock may be technically stretched to the downside. BBP points to seller dominance with a negative bias, further confirmed by the AO's alignment with the prevailing downtrend. Pfizer has fallen $1.42 (5.79%) over the past week, moving from a previous weekly close of $25.22, and is now situated at the very bottom of the weekly range near its support zone. Weekly volatility stands at 5.81%, reflecting a steady decline from the week's high. In today's session, the price is down 1.02%, intensifying the short-term bearish tone.

Further downside risk as probability of rebound remains low

Looking ahead, the forecast range for the next week is $23.50 to $24.50, which reflects the prevailing bearish bias and fits within typical weekly volatility parameters for Pfizer. Relative to its 52-week range ($23.11–$28.74), the stock is trading close to its yearly low. Based on W1 signals (MA-50, RSI, ADX — all "Sell"; MACD is Neutral), the probability of a price increase in the coming week is very low (less than 20%), favoring further weakness. The baseline scenario sees sideways consolidation between $23.50 and $24.50. A bullish scenario would require a break above $24.50, potentially targeting the $25.00–$25.24 resistance cluster, while failure to hold $23.50 could trigger a renewed push toward the 52-week low.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Previously it was reported that Pfizer shares remained under pressure due to a pipeline setback and persistent bearish momentum, contributing to a cautious near-term outlook. This article offers an updated perspective for investors, highlighting the importance of monitoring any shift in sentiment or developments that could catalyze a reversal in the prevailing trend.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.